Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Common Equity (2018 - 2025)

TransMedics has reported Common Equity over the past 8 years, most recently at $473.1 million for Q4 2025.

  • Quarterly results put Common Equity at $473.1 million for Q4 2025, up 106.95% from a year ago — trailing twelve months through Dec 2025 was $473.1 million (up 106.95% YoY), and the annual figure for FY2025 was $473.1 million, up 106.95%.
  • Common Equity for Q4 2025 was $473.1 million at TransMedics, up from $355.2 million in the prior quarter.
  • Over the last five years, Common Equity for TMDX hit a ceiling of $473.1 million in Q4 2025 and a floor of $50.9 million in Q2 2022.
  • Median Common Equity over the past 5 years was $173.4 million (2022), compared with a mean of $181.1 million.
  • Biggest five-year swings in Common Equity: plummeted 42.78% in 2022 and later skyrocketed 221.52% in 2023.
  • TransMedics' Common Equity stood at $67.9 million in 2021, then skyrocketed by 176.14% to $187.4 million in 2022, then fell by 26.78% to $137.2 million in 2023, then surged by 66.62% to $228.6 million in 2024, then skyrocketed by 106.95% to $473.1 million in 2025.
  • The last three reported values for Common Equity were $473.1 million (Q4 2025), $355.2 million (Q3 2025), and $318.1 million (Q2 2025) per Business Quant data.